Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Observational Prospective Study on Patients Treated With Norditropin®

Completed

Conditions: Growth Hormone Disorder
Chronic Renal Insufficiency
Foetal Growth Problem
Adult Growth Hormone Deficiency
Small for Gestational Age
Noonan Syndrome
Growth Hormone Deficiency in Children
Genetic Disorder
Turner Syndrome
Chronic Kidney Disease

Interventions: Drug: somatropin

First Posted Date: 2009-08-17

Last Posted Date: 2017-10-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21249

Registration Number: NCT00960128

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: repaglinide and metformin combination tablet
Drug: repaglinide
Drug: metformin

First Posted Date: 2009-08-14

Last Posted Date: 2015-03-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT00959101

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B

Interventions: Drug: nonacog beta pegol

First Posted Date: 2009-08-11

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT00956345

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B
Healthy

Interventions: Drug: placebo
Drug: activated recombinant human factor VII, long acting

First Posted Date: 2009-08-04

Last Posted Date: 2016-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 38

Registration Number: NCT00951873

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Phase 2

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: activated recombinant human factor VII, long acting

First Posted Date: 2009-08-04

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 23

Registration Number: NCT00951405

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2009-07-22

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT00943501

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone

Phase 2

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: NNC126-0083
Drug: somatropin

First Posted Date: 2009-07-10

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT00936403

Locations: 🇬🇧
Novo Nordisk Investigational Site, Cambridge, United Kingdom

An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Other: No treatment given
Drug: somatropin

First Posted Date: 2009-07-08

Last Posted Date: 2015-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 121

Registration Number: NCT00934063

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

Phase 1

Completed

Conditions: Healthy
Adult Growth Hormone Deficiency
Growth Hormone Disorder

First Posted Date: 2009-07-02

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 86

Registration Number: NCT00931476

Locations: 🇺🇸
Novo Nordisk Investigational Site, Honolulu, Hawaii, United States

Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: activated recombinant human factor VII, long acting

First Posted Date: 2009-06-17

Last Posted Date: 2016-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 8

Registration Number: NCT00922792

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy